• 23 Apr 2019

    2019 Specialty Pharmacy Patient Choice Awards Finalists Announced

    Alexandria DeVries, , Zitter Health Insights

    The Specialty Pharmacy Patient Choice Award was created to recognize specialty pharmacies and their commitment to patient satisfaction. The criteria for this award were formulated by a committee comprised of individuals representing pharmaceutical manufacturers, health plans, pharmacy benefit managers (PBMs), trade organizations, consultants and equity research firms. Rankings for the Patient Choice Awards are based […]

    read more
  • 10 May 2016

    Doctor Communication and Medication Adherence

    Pamela Morris, Director, Syndicated Research, Zitter Health Insights

    A recent large-scale survey found that people living with rheumatoid arthritis (RA) believe that their relationship with their healthcare professional can positively impact the management of their disease.[i] But how does doctor-patient communications influence the patient’s adherence to medication protocols? Our December 2015 Abandonment Insight Monitor (AIM) survey found that RA patients are more than […]

    read more
  • 04 May 2016

    Hassle Factor-How Do Therapeutic Areas Differ?

    Pamela Morris, Director, Syndicated Research, Zitter Health Insights

    The U.S. healthcare system incurs more than $200 billion in avoidable costs every year, and much of this staggering number is attributed to prescription abandonment and non-adherence to recommended drug therapies.1 Simply put, patients who do not fill their prescriptions cannot take the medications as prescribed by their doctor.  Ultimately, patients stop taking a medication […]

    read more
  • 01 Mar 2016

    The benefits of being the fly on the wall

    Colleen Binder, Zitter Health Insights

    Our pharmaceutical customers invest months — sometimes years — and massive resources in preparing a new drug or health technology for market launch.  Both those launching a product and those carefully watching a competitive launch have questions about how the product’s value proposition will resonate with a P&T committee, and what access the product will […]

    read more
  • 04 Nov 2015

    PCSK9 Inhibitors: A New Class of LDL-C Lowering Treatments

    Remy Corvese, Senior Analyst, Zitter Health Insights

    Since their development in the late 1980s, Statins have remained the gold standard in treating and regulating cholesterol production. Blockbuster drugs such as Lipitor (atorvastatin) and Crestor (rosuvastatin) produced annual revenues of over $12B globally in the mid-2000s. However, this blog post will discuss the emergence of a unique alternative treatment in lowering LDL cholesterol […]

    read more